Physician profile
Brandon Everett Scott
NPI 1245798727
$4,977.00
in general payments reported to CMS, 2019-2025
46 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $858 · 2022: $1,067 · 2023: $805 · 2024: $1,035 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,052.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $521.06 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $517.18 | 2021-2025 | Xifaxan, Trulance |
| Lundbeck LLC | $419.66 | 2022-2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $397.85 | 2021-2025 | Rexulti, Nuedexta |
| Amgen INC. | $388.39 | 2021-2024 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $291.77 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Argenx US, INC. | $279.85 | 2023-2025 | Vyvgart Hytrulo |
| Takeda Pharmaceuticals U.S.A., INC. | $182.07 | 2021-2025 | Hyqvia |
| Astrazeneca Pharmaceuticals LP | $171.23 | 2021-2024 | Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $166.20 | 2021-2025 | |
| Ucb, INC. | $164.51 | 2025 | Fintepla, Rystiggo |
| Pfizer INC. | $159.88 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.80 | 2021-2024 | Synjardy, Tradjenta, Jardiance |
| Lilly USA, LLC | $129.12 | 2021-2025 | Mounjaro, Kisunla, Jardiance |
| Nestle Healthcare Nutrition INC. | $113.76 | 2021-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.